Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06471647 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Drugs on Stress Memories
A Early Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
NCT06471647: Completed Early Phase 1 study, sponsored by University of Chicago.
NCT06471647 is a Early Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 36 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06471647, a Early Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
There is evidence that cannabinoids, including delta-9-tetrahydrocannabinol (THC), reduce responses to acute stress and fear-related stimuli, but few studies have examined the effects of THC on memories of stressful experiences. The researchers hypothesize that THC will attenuate behavioral and physiological responses to negative valence stimuli, including memories of aversive experiences.
Primary Outcome
Using a visual analog scale participants will rate feelings of 'distress' 'arousal' and 'valence'. Scores range from 0-100 with higher scores indicating greater responses on particular items
Interventions
- DRUG Placebo
- DRUG delta-9-tetrahydrocannabinol (THC) (5)
- DRUG delta-9-tetrahydrocannabinol (THC) (10)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-03-25 |
| Phase | Early Phase 1 |
What the finished NCT06471647 record still lists
NCT06471647 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06471647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06471647 about?
NCT06471647 is a clinical study titled "Effects of Drugs on Stress Memories". There is evidence that cannabinoids, including delta-9-tetrahydrocannabinol (THC), reduce responses to acute stress and fear-related stimuli, but few studies have examined the effects of THC on memories of stressful experiences. The researchers hypothesize that THC will attenuate behavioral and phys...
What is the current status of trial NCT06471647?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2024-07-01. Estimated completion is 2025-03-25.
What interventions are being tested in trial NCT06471647?
The interventions under investigation include: Placebo (DRUG), delta-9-tetrahydrocannabinol (THC) (5) (DRUG), delta-9-tetrahydrocannabinol (THC) (10) (DRUG).
Who is sponsoring clinical trial NCT06471647?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06471647's enrollment target sits among peer trials
36 712th of 2000 higher than 1,266 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI